InvestorsHub Logo
Followers 13
Posts 2494
Boards Moderated 0
Alias Born 02/04/2014

Re: None

Thursday, 01/06/2022 6:10:20 AM

Thursday, January 06, 2022 6:10:20 AM

Post# of 326
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

insert-text-here


https://www.obseva.com/pressrelease-detail/?pr=4786
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OBSV News